Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Herbst Robinson, Katie J ^a   Liu, Li ^a   James, Michael ^a   Yao, Yuemang ^a   Xie, Sharon X ^a   Brunden, Kurt R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AUTACOID; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; ICOSANOID; PROSTAGLANDIN E2; PROTEIN KINASE C; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR;

ALZHEIMER DISEASE; ANIMAL; BRAIN; CELL CULTURE; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOBLOTTING; MALE; METABOLISM; NERVE CELL; PATHOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELLS, CULTURED; DINOPROSTONE; DISEASE MODELS, ANIMAL; EICOSANOIDS; FEMALE; GENE EXPRESSION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; INFLAMMATION MEDIATORS; MALE; MICE, TRANSGENIC; NEURONS; PROTEIN KINASE C; RATS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THROMBOXANE A2;

EID: 84950241506     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18286     Document Type: Article

References (70)

1. Selkoe, D. J. & Schenk, D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annual Review of Pharmacology and Toxicology 43, 545-584 (2003).
2. Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews. Drug Discovery 10, 698-712 (2011).
3. Lee, V. M. Y., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annual Review of Neuroscience 24, 1121-1159 (2001).
4. Sultana, R. & Butterfield, D. A. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19, 341-353 (2010).
5. Wyss-Coray, T. & Rogers, J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harbor Perspectives in Medicine 2, a006346 (2012).
6. Haga, S., Akai, K. & Ishii, T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol 77, 569-575 (1989).
7. Rogers, J., Luber-Narod, J., Styren, S. D. & Civin, W. H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9, 339-349 (1988).
8. Dumont, M. & Beal, M. F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology & Medicine 51, 1014-1026 (2011).
9. Montine, T. J., Markesbery, W. R., Morrow, J. D. & Roberts, L. J., 2nd. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44, 410-413 (1998).
10. Pratico, D., Lee, V., Trojanowski, J. Q., Rokach, J. & Fitzgerald, G. A. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 12, 1777-1783 (1998).
11. Shineman, D. W., Zhang, B., Leight, S. N., Pratico, D. & Lee, V. M. Y. Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. Journal of Neuroscience 28, 4785-4794 (2008).
12. Soper, J. H. et al. Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease. ACS Chemical Neuroscience 3, 928-940 (2012).
13. Giulian, D., Corpuz, M., Richmond, B., Wendt, E. & Hall, E. R. Activated microglia are the principal glial source of thromboxane in the central nervous system. Neurochemistry International 29, 65-76 (1996).
14. Klegeris, A. & McGeer, P. L. Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP. Journal of Leukocyte Biology 73, 369-378 (2003).
15. Combrinck, M. et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 77, 85-88 (2006).
16. Montine, T. J. et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495-1498 (1999).
17. Nakahata, N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacology & Therapeutics 118, 18-35 (2008).
18. Young, L. H., Balin, B. J. & Weis, M. T. Go 6983: a fast acting protein kinase C inhibitor that attenuates myocardial ischemia/reperfusion injury. Cardiovascular Drug Reviews 23, 255-272 (2005).
19. Narumiya, S., Ishizaki, T. & Uehata, M. Use and properties of ROCK-specific inhibitor Y-27632. Methods in Enzymology 325, 273-284 (2000).
20. Paul, B. Z., Daniel, J. L. & Kunapuli, S. P. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 274, 28293-28300 (1999).
21. Mochly-Rosen, D., Das, K. & Grimes, K. V. Protein kinase C, an elusive therapeutic target? Nature Reviews. Drug Discovery 11, 937-957 (2012).
22. Castagna, M. et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257, 7847-7851 (1982).
23. Liu, C. & Hermann, T. E. Characterization of ionomycin as a calcium ionophore. J Biol Chem 253, 5892-5894 (1978).
24. Wei, L. L. et al. Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer's disease. Neuroscience Bulletin 26, 77-84 (2010).
25. Fang, S. H. et al. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 140, 969-979 (2006).
26. Okubo, M., Yamanaka, H., Kobayashi, K. & Noguchi, K. Leukotriene synthases and the receptors induced by peripheral nerve injury in the spinal cord contribute to the generation of neuropathic pain. Glia 58, 599-610 (2010).
27. Bernstein, P. R. Chemistry and structure-activity relationships of leukotriene receptor antagonists. American Journal of Respiratory and Critical Care Medicine 157, S220-225 (1998).
28. Watanabe, K. et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59, 5093-5096 (1999).
29. Juteau, H. et al. Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry. Bioorg Med Chem Lett 11, 747-749 (2001).
30. Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 26, 10129-10140 (2006).
31. Lee, E. B. et al. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. The Journal of Cell Biology 168, 291-302 (2005).
32. Manev, H., Chen, H., Dzitoyeva, S. & Manev, R. Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease. Progress in Neuro- Psychopharmacology & Biological Psychiatry 35, 315-319 (2011).
33. Choi, S. H. et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem 124, 59-68 (2013).
34. Warner, T. D. & Mitchell, J. A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18, 790-804 (2004).
35. Kulkarni, S. K. & Singh, V. P. Licofelone: the answer to unmet needs in osteoarthritis therapy? Current Rheumatology Reports 10, 43-48 (2008).
36. Eketjall, S. et al. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J Neurosci 33, 10075-10084 (2013).
37. Buxbaum, J. D. et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proceedings of the National Academy of Sciences of the United States of America 89, 10075-10078 (1992).
38. Yeon, S. W. et al. Blockade of PKC epsilon activation attenuates phorbol ester-induced increase of alpha-secretase-derived secreted form of amyloid precursor protein. Biochemical and Biophysical Research Communications 280, 782-787 (2001).
39. da Cruz e Silva, O. A. et al. Enhanced generation of Alzheimer's amyloid-beta following chronic exposure to phorbol ester correlates with differential effects on alpha and epsilon isozymes of protein kinase C. Journal of Neurochemistry 108, 319-330 (2009).
40. Zhen, G. et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease. Neurobiol Aging 33, 2215-2219 (2012).
41. Shi, J. et al. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol 72, 788-798 (2012).
42. Liang, X. et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 25, 10180-10187 (2005).
43. Hoshino, T. et al. Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP(4) receptor. J Neurochem 120, 795-805 (2012).
44. Woodling, N. S. et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci 34, 5882-5894 (2014).
45. Lee, R. K., Knapp, S. & Wurtman, R. J. Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J Neurosci 19, 940-947 (1999).
46. Pooler, A. M., Arjona, A. A., Lee, R. K. & Wurtman, R. J. Prostaglandin E2 regulates amyloid precursor protein expression via the EP2 receptor in cultured rat microglia. Neurosci Lett 362, 127-130 (2004).
47. Tang, S. S. et al. Leukotriene D4 induces cognitive impairment through enhancement of CysLT(1) R-mediated amyloid-beta generation in mice. Neuropharmacology 65, 182-192 (2013).
48. Firuzi, O., Zhuo, J., Chinnici, C. M., Wisniewski, T. & Pratico, D. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 22, 1169-1178 (2008).
49. Chu, J. & Pratico, D. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of gamma-secretase. The American Journal of Pathology 178, 1762-1769 (2011).
50. Hillmann, A. et al. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 33, 833 e839-850 (2012).
51. McGeer, P. L. & McGeer, E. G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28, 639-647 (2007).
52. Kukar, T. et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11, 545-550 (2005).
53. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
54. Szekely, C. A. et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23, 159-169 (2004).
55. Leoutsakos, J. M., Muthen, B. O., Breitner, J. C. & Lyketsos, C. G. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. International Journal of Geriatric Psychiatry 27, 364-374 (2012).
56. Martin, B. K. et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65, 896-905 (2008).
57. Szekely, C. A. et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70, 2291-2298 (2008).
58. Breitner, J. C. et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association 7, 402-411 (2011).
59. Maxis, K. et al. The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein. Arthritis Research & Therapy 8, R181 (2006).
60. Duffield-Lillico, A. J. et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prevention Research 2, 322-329 (2009).
61. Hwang, S. H. W., Wecksler A. T., Wagner, K. & Hammock, B. D. Rationally designed mutlitarget agents against inflammation and pain. Curr Med Chem 20, 1783-1799 (2013).
62. Kitamura, Y. et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 254, 582-586 (1999).
63. Fujimi, K. et al. Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: the Hisayama Study. Dementia and Geriatric Cognitive Disorders 23, 423-431 (2007).
64. Montine, T. J., Sonnen, J. A., Milne, G., Baker, L. D. & Breitner, J. C. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PloS one 5, e9340 (2010).
65. Brune, K. Safety of anti-inflammatory treatment-new ways of thinking. Rheumatology 43Suppl 1, i16-20 (2004).
66. Vitek, M. P. Increasing amyloid peptide precursor production and its impact on Alzheimer's disease. Neurobiology of Aging 10, 471-473 (1989).
67. Palmert, M. R. et al. Amyloid protein precursor messenger RNAs: differential expression in Alzheimer's disease. Science 241, 1080-1084 (1988).
68. Weidemann, A. et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57, 115-126 (1989).
69. Turner, R. S., Suzuki, N., Chyung, A. S., Younkin, S. G. & Lee, V. M. Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 271, 8966-8970 (1996).
70. Golovko, M. Y. & Murphy, E. J. An improved LC-MS/MS procedure for brain prostanoid analysis using brain fixation with headfocused microwave irradiation and liquid-liquid extraction. Journal of Lipid Research 49, 893-902 (2008).